Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System

Paul N. Pfeiffer, MD ; Jamarie Geller, MD ; Dara Ganoczy, MPH ; Jennifer Jagusch, MSW ; John Carty, MD ; Fe Erlita D. Festin, MD ; William S. Gilmer, MD; ; Brian Martis, MD ; Mohini Ranganathan, MD ; Ilse R. Wiechers, MD ; Avinash Hosanagar, MD

J Clin Psychiatry 2024;85(1):23m14984

ABSTRACT

Objective/Background: Intravenous (IV) ketamine is effective for reducing symptoms of major depressive disorder in short-term clinical trials; this study characterized clinical outcomes of repeated infusions in routine clinical practice and the frequency and number of infusions used to sustain symptom improvement.

Methods: Records of IV ketamine infusions for depression and associated Patient Health Questionnaire-9 (PHQ-9) scores were identified from Veterans Health Administration (VA) electronic medical records for patients treated in Fiscal Year 2020 and up to 12 months following the date of their first infusion.

Results: Sample patients (n = 215) had a mean baseline PHQ-9 score of 18.6 and a mean of 2.1 antidepressant medication trials in the past year and 6.1 antidepressant trials in the 20 years prior to their first ketamine infusion. Frequency of infusions decreased from every 5 days to every 3–4 weeks over the first 5 months of infusions, with a mean of 18 total infusions over 12 months. After 6 weeks of treatment, 26% had a 50% improvement in PHQ-9 score (response) and 15% had PHQ-9 score ≤ 5 (remission). These improvements were similar at 12 and 26 weeks. No demographic characteristics or comorbid diagnoses were associated with 6-week PHQ-9 scores.

Conclusions: While only a minority of patients treated with IV ketamine for depression experienced response or remission, symptom improvements achieved within the first 6 weeks were sustained over at least 6 months with decreasing infusion frequency. Further study is needed to determine optimal infusion frequency and potential for adverse effects with repeated ketamine infusions for depression.

J Clin Psychiatry 2024;85(1):23m14984

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (33)

Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–346. PubMed CrossRef
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. PubMed CrossRef
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Washington, DC: US Government Printing Office. 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/
Zivin K, Ilgen MA, Pfeiffer PN, et al. Early mortality and years of potential life lost among Veterans Affairs patients with depression. Psychiatr Serv. 2012;63(8):823–826. PubMed CrossRef
Louzon SA, Bossarte R, McCarthy JF, et al. Does suicidal ideation as measured by the PHQ-9 predict suicide among VA patients? Psychiatr Serv. 2016;67(5):517–522. PubMed CrossRef
Ilgen MA, Bohnert ASB, Ignacio RV, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. 2010;67(11):1152–1158. PubMed CrossRef
Scherrer JF, Garfield LD, Chrusciel T, et al. Increased risk of myocardial infarction in depressed patients with type 2 diabetes. Diabetes Care. 2011;34(8):1729–1734. PubMed CrossRef
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
Pfeiffer PN, Zivin K, Hosanagar A, et al. Assessment of outcome-based measures of depression care quality in Veterans Health Administration facilities. J Behav Health Serv Res. 2023;50(1):49–67. PubMed CrossRef
Oslin DW, Lynch KG, Shih MC, et al; PRIME Care Research Group. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME care randomized clinical trial. JAMA. 2022;328(2):151–161. PubMed CrossRef
Szukis H, Joshi K, Huang A, et al. Economic burden of treatment-resistant depression among veterans in the United States. Curr Med Res Opin. 2021;37(8):1393–1401. PubMed CrossRef
Vermeiden M, Kamperman AM, Vulink ME, et al. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl). 2015;232(8):1347–1356. PubMed CrossRef
Kho KH, van Vreeswijk MF, Simpson S, et al. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003;19(3):139–147. PubMed CrossRef
Pfeiffer PN, Bowersox N, Birgenheir D, et al. Preferences and barriers to care following psychiatric hospitalization at two Veterans Affairs Medical Centers: a mixed methods study. J Behav Health Serv Res. 2016;43(1):88–103. PubMed CrossRef
Pfeiffer PN, Valenstein M, Hoggatt KJ, et al. Electroconvulsive therapy for major depression within the Veterans Health Administration. J Affect Disord. 2011;130(1-2):21–25. PubMed CrossRef
Andrade C, Arumugham SS, Thirthalli J. Adverse effects of electroconvulsive therapy. Psychiatr Clin North Am. 2016;39(3):513–530. PubMed CrossRef
Shinohara R, Aghajanian GK, Abdallah CG. Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities. Biol Psychiatry. 2021;90(2):85–95. PubMed CrossRef
Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543–562. PubMed CrossRef
Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709. PubMed CrossRef
Oliver PA, Snyder AD, Feinn R, et al. Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: a retrospective chart review. J Clin Psychiatry. 2022;83(6):21m14336. PubMed CrossRef
Levinta A, Meshkat S, McIntyre RS, et al. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: a systematic review. J Affect Disord. 2022;318:139–149. PubMed CrossRef
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef
Löwe B, Unützer J, Callahan CM, et al. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004;42(12):1194–1201. PubMed CrossRef
Coley RY, Boggs JM, Beck A, et al. Defining success in measurement-based care for depression: a comparison of common metrics. Psychiatr Serv. 2020;71(4):312–318. PubMed CrossRef
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. PubMed CrossRef
Agha Z, Lofgren RP, VanRuiswyk JV, et al. Are patients at Veterans Affairs medical centers sicker? a comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252–3257. PubMed CrossRef
Madore MR, Kozel FA, Williams LM, et al. Prefrontal transcranial magnetic stimulation for depression in US military veterans: a naturalistic cohort study in the Veterans Health Administration. J Affect Disord. 2022;297:671–678. PubMed CrossRef
McIntyre RS, Rodrigues NB, Lipsitz O, et al. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in adults with treatment-resistant depression receiving intravenous ketamine treatment. J Affect Disord. 2021;288:210–216. PubMed CrossRef
Lapidos A, Lopez-Vives D, Sera CE, et al. Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. J Affect Disord. 2023;323:534–539. PubMed CrossRef
Price RB, Kissel N, Baumeister A, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators. Mol Psychiatry. 2022;27(12):5096–5112. PubMed CrossRef
Yesavage JA, Fairchild JK, Mi Z, et al; VA Cooperative Studies Program Study Team. Effect of repetitive transcranial magnetic stimulation on treatment-resistant major depression in us veterans: a randomized clinical trial. JAMA Psychiatry. 2018;75(9):884–893. PubMed CrossRef
Feder A, Costi S, Rutter SB, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193–202. PubMed CrossRef
Smith-Apeldoorn SY, Veraart JK, Spijker J, et al. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907–921. PubMed CrossRef